LIMITATIONS AND USAGES OF CEFOVECIN IN ZOOLOGICAL PRACTICE

BERTELSEN MF¹, THUESEN LR², BAKKER J³, HEBEL C⁴, GRØNDAHL C¹, BRIMER L², SKAANILD MT²

¹Center for Zoo and Wild Animal Health, Copenhagen Zoo, Roskildevej 38, DK-2000 Frederiksberg, DENMARK; mfb@zoo.dk

²Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, DENMARK

³Biomedical Primate Research Centre, Lange Kleiweg 139, 2288GJ Rijswijk, THE NETHERLANDS

⁴Al Wabra Wildlife Preservation, P.O. Box 44069, Doha, STATE OF QATAR

The 3rd generation cephalosporin cefovecin (Convenia, Pfizer) has an exceptionally long elimination half-life in dogs and cats, giving rise to a 14 day treatment interval in these species (STEGEMANN et al., 2006 a, b). Long treatment intervals are highly desirable in many exotic species in which oral medication is difficult and daily injections may be stressful and/or logistically difficult. However, pharmacokinetic profiles may differ greatly among species potentially leading to treatment failure, toxicity or development of antibiotic resistance.

Table 1: Theoretical cefovecin treatment intervals (Txi) in selected species based on a MIC of 1 µg/ml, a dose of 10 mg/kg cefovecin, and data from clinical trials or controlled studies.

Species	Scientific name	n	Likely Txi	Ref
Scarlet ibis	Eudocimus ruber	2	≈ 2h	1
African grey parrot	Psittacus erithacus	1	< 2h	1
Blue-fronted amazon	Amazona aestiva	2	< 2h	1
Laughing dove	Streptopelia senegalensis	6. en 5.a 1 55	< 2h	+
Domestic chicken	Gallus gallus	8	≈1h	1
Russian tortoise	Testudo horsfieldii	1	< 24h	1
Spur-thighed tortoise	Testudo graeca	1	< 24h	1
Russian ratsnake	Elaphe schrenckii	2	≈ 24h	1
Boa constrictor	Boa constrictor	1	≈ 24h	1
Central bearded dragon	Pogona vitticeps	1	> 24h	1
Green iguana	Iguana iguana	16	≈ 15h	1
Ring tailed lemur	Lemur catta	1	> 5d	+
Geoffroy's spider monkey	Ateles geoffroyi	1	< 48h	+
Rhesus macaques	Macacca mulatta	2	≈ 24h	+
Domestic dog	Canis familiaris	12	14d	3
Domestic cat	Felis catus	12	14d	2
Caracal lynx	Felis caracal	3	≈ 10d	+
Amur tiger	Panthera tigris	1	> 14d	+
African lion	Panthera leo	3	≈ 10d	+
Domestic goat	Capra hircus	1	< 24h	+
Soemmerring's gazelle	Nanger soemmerringii	- 1	< 24h	+
Rheem gazelle	Gazella subgutturosa marica	1	< 24h	+
Speke's gazelle	Gazella spekei	1	< 24h	+
Domestic pig	Sus scrofa	1	> 5d	+

In a series of experiments and clinical trials, we investigated pharmacokinetic parameters for cefovecin in multiple species following a single treatment (10 mg/kg, body weight).

Full pharmacokinetic profiles were generated in chickens and green iguanas (THUESEN et al., 2009); kinetics were characterised by rapid absorption and the mean plasma half-life for cefovecin was $52 \pm 16 \, \text{min} (0.9 \pm 0.3 \, \text{hrs})$ for hens and $3.9 \, \text{hrs}$ in green iguanas.

Results of brief elimination studies (Tab. 1) in 9 additional species of birds and reptiles, as well as 4 species of ruminants and 2 species of primates were similar to those seen in chickens and green iguanas. In contrast, 3 feline species, ring tailed lemurs, and domestic swine showed much longer half lives. No clinical signs of adverse effects were detected in any species.

Based on these findings, cefovecin may be effective with long treatment intervals (5 - 14 days) in exotic felids and possibly lemurs and pigs, but is not suitable for long dosing interval treatment in birds, reptiles, ruminants or primates.

References

- STEGEMANN MR, SHERINGTON J, BLANCHFLOWER S (2006a). Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther **29**, 501 511.
- STEGEMANN MR, SHERINGTON J, COATI N, BROWN SA, BLANCHFLOWER S (2006b). Pharmacokinetics of cefovecin in cats. J Vet Pharmacol Ther **29**, 513 524.
- THUESEN LR, MF BERTELSEN, L BRIMER, MT SKAANILD (2009). Selected pharmacokinetic parameters for Cefovecin in hens and green iguanas. J Vet Pharmacol Ther 32, 613 617.